2018 ASCO: Genomic Study Finds Lynch Syndrome Is Common Among Patients With MSI-High Tumors
A genomic study of more than 15,000 tumor samples showed that people who have tumors with high microsatellite instability (MSI-H)—a genomic marker associated with a large number of genetic mutations in the tumor—are more likely to have Lynch syndrome, a hereditary condition that increases a person’s risk of developing many different types of cancer. Among people with MSI-H tumors, 16% were subsequently found to have Lynch syndrome. Researchers also found that Lynch syndrome is linked to more types of cancer than previously thought. The study was featured in a press briefing today and will be presented by Stadler et al at the 2018 ASCO Annual Meeting (Abstract LBA1509).
“Our findings suggest that all patients with MSI-H tumors should be tested for Lynch syndrome, regardless of cancer type or family or personal history of cancer,” said senior study author Zsofia Kinga Stadler, MD, Clinic Director of the Clinical Genetics Service and a medical oncologist at Memorial Sloan Kettering Cancer Center. “Diagnosing Lynch syndrome gives us the unique opportunity of helping not only our cancer patients, but also at-risk family members, as their cancer risk can be lowered through increased cancer surveillance and, in some cases, preventive surgery.”
About Lynch Syndrome and MSI
It is estimated that about 1 in 300 (0.3%) people in the general population has Lynch syndrome, which increases a person’s risk of developing several cancers. The most common cancers associated with Lynch syndrome are colorectal and endometrial, but people with Lynch syndrome also have a higher risk of developing other gastrointestinal cancers, as well as ovarian, brain, and skin cancers. The hallmark of Lynch syndrome–associated tumors is MSI-H.
MSI is a genomic marker that indicates a defect in a cell’s ability to repair damaged DNA, resulting in the accumulation of mutations. Traditionally, MSI testing has been performed on colorectal and endometrial cancers as an initial screening test to identify patients who may be at risk for having Lynch syndrome. Since the U.S. Food and Drug Administration approved the immunotherapy pembrolizumab (Keytruda) in 2017 for use in all MSI-H tumors, regardless of tumor type, MSI testing of tumors has become broadly used to identify patients who may benefit from pembrolizumab.
About the Study
Researchers analyzed more than 15,000 tumor samples collected from patients with more than 50 different types of advanced cancer using a comprehensive genomic test called MSK-IMPACT. All study participants were part of a prospective study of MSK-IMPACT and received cancer treatment at Memorial Sloan Kettering Cancer Center. The test uses next-generation sequencing to look for mutations in hundreds of cancer-related genes, as well as other molecular changes, including MSI status.
Researchers also tested blood samples from study participants for inherited mutations in genes involved in DNA repair: MLH1, MSH2, MSH6, PMS2, and EPCAM. Mutations in these genes cause Lynch syndrome. Tumors caused by Lynch syndrome have mismatch repair deficiency (MMR-D) and are MSI-H.
Key Findings
Based on the results of the genomic analysis, the tumor samples were classified into three groups: MSI-stable (MSS, no MSI instability found), MSI-indeterminate (MSI-I, moderate level of MSI), and MSI-H. The vast majority (93.2%) of tumors were found to be MSS; 4.6% were MSI-I; and 2.2% were MSI-H. Inherited mutations in Lynch syndrome–associated genes were found in 16% of people with MSI-H tumors, compared to 1.9% of those with MSI-I tumors and only 0.3% of those with MSS tumors.
As expected, about 25% of the 1,025 MSI-H/MSI-I tumors were colorectal or endometrial cancers. These are the most common cancers linked to Lynch syndrome, and MSI testing is routinely performed on such tumors. However, nearly 50% of patients with MSI-H/MSI-I tumors who were identified as having Lynch syndrome had cancer types not previously, or rarely, linked to the syndrome, including mesothelioma, sarcoma, adrenocortical cancer, melanoma, prostate cancer, and ovarian germ cell cancer. Of these patients, 45% did not meet Lynch syndrome genetic testing criteria based on family or personal cancer history. According to the authors, this suggests that Lynch syndrome is linked to a broader spectrum of cancers than previously thought and that MSI-H/MMR-D is predictive of Lynch syndrome, regardless of cancer type.
In the final step of the study, 57 MSI-I/MSI-H tumor samples were also tested for abnormal DNA repair proteins—and MMR-D was found in nearly all (98.3%) of those tumors. These findings suggest that if either MSI-H or MMR-D is found in the tumor, hereditary genetic testing for Lynch syndrome should be performed.
Next Steps
The chance of developing certain cancers linked to Lynch syndrome can be lowered through frequent screening (eg, yearly colonoscopy and endoscopy for gastrointestinal cancers) and preventive surgery (eg, removal of the uterus and ovaries for gynecologic cancers). More research is needed to develop screening and preventive strategies for other cancers linked to Lynch syndrome.
Commentary
“This study enhances our ability to catch Lynch syndrome where it may have been previously overlooked, thanks in large part to advances in precision medicine. This gives us a valuable opening to preempt future cancers in our patients through better, earlier, and more accurate diagnosis of Lynch syndrome,” said ASCO Expert Shannon Westin, MD.
This study received funding from the Romeo Milio Lynch Syndrome Foundation, the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, the Robert and Kate Niehaus Center for Inherited Cancer Genomics, the Fieldstone Family Fund, a Stand Up To Cancer Colorectal Cancer Dream Team Translational Research Grant (SU2C-AACR-DT22-17), and the NIH/NCI Cancer Center Support Grant (P30 CA008748).
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
